Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 2/20 | 0.75 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.75 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.75 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.75 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.75 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.75 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.75 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.75 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.75 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.75 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | NAMPT | P43490 | 1/20 | 0.61 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13299860 | 1.00 | HDAC3 (0.75) | HDAC3HDAC1HDAC4HDAC7HDAC2 | |
| Hydrochloric Acid SCHEMBL3128502 | 0.99 | HDAC3 (0.73) | HDAC3HDAC1HDAC4HDAC7HDAC2 | |
| SCHEMBL5849288 | 0.94 | SMN1; SMN2 (0.72) | HDAC3HDAC1HDAC4HDAC7HDAC2 | |
| SCHEMBL3188696 | 0.88 | KMT2A (0.71) | HDAC3HDAC1HDAC4HDAC7HDAC2 | |
| SCHEMBL8516755 | 0.86 | SMN1; SMN2 (0.90) | HDAC3HDAC1HDAC4HDAC7HDAC2 | |
| SCHEMBL8293662 | 0.85 | SMN1; SMN2 (0.90) | HDAC3HDAC1HDAC4HDAC7HDAC2 | |
| SCHEMBL3133476 | 0.85 | SMN1; SMN2 (0.90) | HDAC3HDAC1HDAC4HDAC7HDAC2 | |
| SCHEMBL24011624 | 0.84 | SMN1; SMN2 (0.70) | HDAC3HDAC1HDAC4HDAC7HDAC2 | |
| SCHEMBL14786047 | 0.84 | SMN1; SMN2 (0.70) | HDAC3HDAC1HDAC4HDAC7HDAC2 | |
| SCHEMBL22170879 | 0.84 | SMN1; SMN2 (0.70) | HDAC3HDAC1HDAC4HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220133685-A1 | FAST-ACTING PLANT-BASED MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS | RECEPTOR HOLDINGS, INC. (US) | 2022-05-05 | — | — | US | disclosed |
| US-11246852-B2 | Fast-acting plant-based medicinal compounds and nutritional supplements | RECEPTOR HOLDINGS, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| EP-2409569-B1 | Method for administering GLP-1 molecules | EMISPHERE TECH INC (US) | 2017-08-16 | — | — | EP | disclosed |
| EP-1478233-B1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | EMISPHERE TECH INC (US) | 2016-11-09 | — | — | EP | disclosed |
| US-20150202296-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2015-07-23 | — | — | US | disclosed |
| US-20150202296-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2015-07-23 | — | — | US | disclosed |
| US-8492330-B2 | Formulation comprising GLP-1 | EMISPHERE TECHNOLOGIES, INC. (US) | 2013-07-23 | — | — | US | disclosed |
| US-8492330-B2 | Formulation comprising GLP-1 | EMISPHERE TECHNOLOGIES, INC. (US) | 2013-07-23 | — | — | US | disclosed |
| EP-2409569-A2 | Method for administering GLP-1 molecules | Emisphere Technologies, Inc. (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20110178006-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | EMISPHERE TECHNOLOGIES, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| US-20110178006-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | EMISPHERE TECHNOLOGIES, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| US-7939494-B2 | Method for administering GLP-1 molecules | EMISPHERE TECHNOLOGIES, INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-7939494-B2 | Method for administering GLP-1 molecules | EMISPHERE TECHNOLOGIES, INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-20090286735-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2009-11-19 | — | — | US | disclosed |
| US-20090286735-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2009-11-19 | — | — | US | disclosed |
| US-7417022-B2 | Compounds and compositions for delivering active agents | MHR INSTITUTIONAL PARTNERS IIA LP (US) | 2008-08-26 | — | — | US | disclosed |
| US-7417022-B2 | Compounds and compositions for delivering active agents | MHR INSTITUTIONAL PARTNERS IIA LP (US) | 2008-08-26 | — | — | US | disclosed |
| EP-1792624-A1 | Modified amino acids and compositions comprising them for delivering active agents | Emisphere Technologies, Inc. (US) | 2007-06-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11246852-B2 | Fast-acting plant-based medicinal compounds and nutritional supplements | SLC1A5, SLC43A1, SLC27A2 | HDAC3 1689/4885HDAC1 1809/4885HDAC4 1168/4885 |
| US-20150202296-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | GLP1R, GIPR, GPR119 | HDAC3 2912/4885HDAC1 3498/4885HDAC4 3003/4885 |
| US-20110178006-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | GLP1R, GIPR, GPR119 | HDAC3 2912/4885HDAC1 3498/4885HDAC4 3003/4885 |
| US-20090286735-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | GLP1R, GIPR, GPR119 | HDAC3 2912/4885HDAC1 3498/4885HDAC4 3003/4885 |
| US-20220133685-A1 | FAST-ACTING PLANT-BASED MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS | SLC1A5, SLC43A1, SLC27A2 | HDAC3 1689/4885HDAC1 1809/4885HDAC4 1168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.